Advertisement

Establishing EDI for a Clinical Trial of a Treatment for Chikungunya

  • Cynthia Dickerson
  • Mark Ensor
  • Robert A. Lodder
Conference paper
Part of the Lecture Notes in Computer Science book series (LNCS, volume 10861)

Abstract

Ellagic acid (EA) is a polyphenolic compound with antiviral activity against chikungunya, a rapidly spreading new tropical disease transmitted to humans by mosquitoes and now affecting millions worldwide. The most common symptoms of chikungunya virus infection are fever and joint pain. Other manifestations of infection can include encephalitis and an arthritic joint swelling with pain that may persist for months or years after the initial infection. The disease has recently spread to the U.S.A., with locally-transmitted cases of chikungunya virus reported in Florida. There is no approved vaccine to prevent or medicine to treat chikungunya virus infections. In this study, the Estimated Daily Intake (EDI) of EA from the food supply established using the National Health and Nutrition Examination Survey (NHANES) is used to set a maximum dose of an EA formulation for a high priority clinical trial.

Keywords

Tropical disease NHANES Drug development 

References

  1. 1.
    Park, S., Kang, Y.: Dietary ellagic acid suppresses atherosclerotic lesion formation and vascular inflammation in apoE-deficient mice. FASEB J. 27(1), 861-23 (2013)Google Scholar
  2. 2.
    García-Niño, R.W., Zazueta, C.: Ellagic acid: pharmacological activities and molecular mechanisms involved in liver protection. Pharmacol. Res. 97, 84–103 (2015)CrossRefGoogle Scholar
  3. 3.
    Kaur, P., Thiruchelvan, M., Lee, R.C.H., Chen, H., Chen, K.C., Ng, M.L., Chu, J.J.H.: Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob. Agents Chemother. 57(1), 155–167 (2013)CrossRefGoogle Scholar
  4. 4.
    Cerdá, B., et al.: Identification of urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds. J. Agric. Food Chem. 53(14), 5571–5576 (2005)CrossRefGoogle Scholar
  5. 5.
    Cerdá, B., et al.: The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy–6H–dibenzopyran–6–one derivatives by the colonic microflora of healthy humans. Eur. J. Nutr. 43(4), 205–220 (2004)CrossRefGoogle Scholar
  6. 6.
    Cerdá, B., Tomás-Barberán, F.A., Espín, J.C.: Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J. Agric. Food Chem. 53(2), 227–235 (2005)CrossRefGoogle Scholar
  7. 7.
    Espín, J.C., et al.: Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J. Agric. Food Chem. 55(25), 10476–10485 (2007)CrossRefGoogle Scholar
  8. 8.
    Mertens-Talcott, S.U., et al.: Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J. Agric. Food Chem. 54(23), 8956–8961 (2006)CrossRefGoogle Scholar
  9. 9.
    Seeram, N.P., Lee, R., Heber, D.: Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin. Chim. Acta 348(1), 63–68 (2004)CrossRefGoogle Scholar
  10. 10.
    Seeram, N.P., et al.: Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J. Nutr. 136(10), 2481–2485 (2006)CrossRefGoogle Scholar
  11. 11.
    Tomás-Barberan, F.A., Espín, J.C., García-Conesa, M.T.: Bioavailability and metabolism of ellagic acid and ellagitannins. Chem. Biol. Ellagitannins 7, 293–297 (2009)Google Scholar
  12. 12.
    González-Barrio, R., et al.: UV and MS identification of urolithins and nasutins, the bioavailable metabolites of ellagitannins and ellagic acid in different mammals. J. Agric. Food Chem. 59(4), 1152–1162 (2011)CrossRefGoogle Scholar
  13. 13.
    Espín, J.C., et al.: Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evid. Based Complement. Altern. Med. 2013, 1–15 (2013)CrossRefGoogle Scholar
  14. 14.
    Larrosa, M., et al.: Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J. Nutr. Biochem. 21(8), 717–725 (2010)CrossRefGoogle Scholar
  15. 15.
    Ishimoto, H., et al.: In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg. Med. Chem. Lett. 21(19), 5901–5904 (2011)CrossRefGoogle Scholar
  16. 16.
    Piwowarski, J.P., et al.: Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials. J. Ethnopharmacol. 155(1), 801–809 (2014)CrossRefGoogle Scholar
  17. 17.
    Adams, L.S., et al.: Pomegranate ellagitannin–derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prevent. Res. 3(1), 108–113 (2010)CrossRefGoogle Scholar
  18. 18.
    Seeram, N.P., et al.: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J. Nutr. Biochem. 16(6), 360–367 (2005)CrossRefGoogle Scholar
  19. 19.
    Seeram, N.P., Aronson, W.J., Zhang, Y., Henning, S.M., Moro, A., Lee, R.P., Sartippour, M., Harris, D.M., Rettig, M., Suchard, M.A., Pantuck, A.J.: Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem. 55(19), 7732–7737 (2007)CrossRefGoogle Scholar
  20. 20.
    Larrosa, M., et al.: Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J. Agric. Food Chem. 54(5), 1611–1620 (2006)CrossRefGoogle Scholar
  21. 21.
    Liu, W., et al.: Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species. Food Funct. 5(11), 2996–3004 (2014)CrossRefGoogle Scholar
  22. 22.
    Bialonska, D., et al.: Urolithins, intestinal microbial metabolites of pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. J. Agric. Food Chem. 57(21), 10181–10186 (2009)CrossRefGoogle Scholar
  23. 23.
    Giménez-Bastida, J.A., et al.: Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit quorum sensing in Yersinia enterocolitica: phenotypic response and associated molecular changes. Food Chem. 132(3), 1465–1474 (2012)CrossRefGoogle Scholar
  24. 24.
    González-Barrio, R., et al.: Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. J. Agric. Food Chem. 58(7), 3933–3939 (2010)CrossRefGoogle Scholar
  25. 25.
    Tomás-Barberán, F.A., et al.: Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J. Agric. Food Chem. 62(28), 6535–6538 (2014)CrossRefGoogle Scholar
  26. 26.
    Truchado, P., et al.: Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. J. Agric. Food Chem. 60(23), 5749–5754 (2011)CrossRefGoogle Scholar
  27. 27.
    CDC 2006: Analytical and Reporting Guidelines: The National Health and Nutrition Examination Survey (NHANES). National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf
  28. 28.
    USDA 2012: What We Eat In America (WWEIA), NHANES: overview. http://www.ars.usda.gov/Services/docs.htm?docid=13793#release. Accessed 29 Jan 2018
  29. 29.
    Bodner-Montville, J., Ahuja, J.K.C., Ingwersen, L.A., Haggerty, E.S., Enns, C.W., Perloff, B.P.: USDA food and nutrient database for dietary studies: released on the web. J. Food Compos. Anal. 19(Suppl. 1), S100–S107 (2006)CrossRefGoogle Scholar
  30. 30.
    Hayes, A.W., Kruger, C.L. (eds.): Hayes’ Principles and Methods of Toxicology, 6th edn, p. 631. CRC Press, Boca Raton (2014)Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Cynthia Dickerson
    • 1
  • Mark Ensor
    • 1
  • Robert A. Lodder
    • 1
  1. 1.University of KentuckyLexingtonUSA

Personalised recommendations